Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors Abstract #55

Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Aim(s): We investigated a novel combination of drugs including daily low dose temozolamide chemotherapy, bevacizumab a monoclonal antibody targeting the vascular endothelial growth factor and somatostatin analogue.
Materials and methods: From July 2008 to June 2009, 13 patients with previously treated and progressive metastatic GEPNETs received oral temozolamide 100 mg/day, intravenous bevacizumab 7.5 mg/m2 every three weeks and the long-acting somatostatin analogue octreotide 30 mg subcutaneously every three weeks (TeBeSa). There were nine men (median age 64 years, range 47-78) with four functioning and nine non-functioning tumors (seven pancreatic, four small intestine, one gastric, and one of unknown primary). Before TeBeSa therapy, nine patients had received first-line therapy (Cisplatin/etoposide: 6pts, streptozotocin/5-FU: 2 pts and Everolimus: 1pt), three patients two lines and one patient three lines of therapy. There were no available archived tissues for testing AGAT expression with immunohistochemistry in any of these patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou

To read results and conclusion, please login ...

Further abstracts you may be interested in

#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#82 A case of insulinoma successfully treated by means of long-acting somatostatin analogue
Introduction: Insulinoma is the most common hormonally active pancreatic neuroendocrine tumor. Effective treatment represents tumor surgery and medical therapy using diazoxide or streptozotocine. Somatostatin analogue therapy is rarely effective in this type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Marek Bolanowski
#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr merav Fraenkel
#1094 Experience with Bevacizumab in Neuroendocrine Tumors
Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis